Exelixis
EXEL
#1697
Rank
NZ$17.02 B
Marketcap
$59.63
Share price
0.52%
Change (1 day)
70.11%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.47

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.48. In 2022 the company made an earnings per share (EPS) of $0.98 a decrease over its 2021 EPS that were of $1.27.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.47-52.12%
2022$0.98-22.97%
2021$1.27100%
2020$0.63-65.09%
2019$1.81-53.91%
2018$3.94333.96%
2017$0.91-260.61%
2016-$0.56-58.75%
2015-$1.37-42.45%
2014-$2.385.3%
2013-$2.2643.48%
2012-$1.57-264.29%
2011$0.96-165.88%
2010-$1.46-32.54%
2009-$2.16-17.65%
2008-$2.6275.86%
2007-$1.49-25.64%
2006-$2.008.33%
2005-$1.85-42.86%
2004-$3.2430.34%
2003-$2.48-5.23%
2002-$2.62-0.65%
2001-$2.64-51.88%
2000-$5.48

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$5.99 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$5.44 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$3.12 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.80 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$24.22 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$24.11 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$3.18 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$17.12-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.44-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA